A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).

Treat-to-target in axial spondyloarthritis — what about physical function and activity?

Etanercept Withdrawal and Retreatment in Nonradiographic Axial Spondyloarthritis: Results of RE-EMBARK, an Open-Label Phase IV Trial

Analysis of Single‐Cell Transcriptome and Surface Protein Expression in Ankylosing Spondylitis Identifies OX40‐Positive and Glucocorticoid‐Induced Tumor Necrosis Factor Receptor–Positive Pathogenic Th17 Cells - Yi - 2023 - Arthritis & Rheumatology - Wiley

Full article: Impact of different types of exercise programs on ankylosing spondylitis: a systematic review and meta-analysis

IJMS, Free Full-Text

Proefschrift vd berg by Nicole Nijhuis - Issuu

Reduction of anterior uveitis flares in patients with axial spondyloarthritis on certolizumab pegol treatment: final 2-year results from the multicenter phase IV C-VIEW study - Irene E. van der Horst-Bruinsma, Rianne E.

Comparison of non-radiographic axial spondyloarthritis and ankylosing spondylitis patients – baseline characteristics, treatment adherence, and development of clinical variables during three years of anti-TNF therapy in clinical practice – topic of

Induction of Sustained Clinical Remission in Early Axial Spondyloarthritis Following Certolizumab Pegol Treatment: 48-Week Outcomes from C-OPTIMISE

New evidence on the management of spondyloarthritis